DECEMBER 2020, VOLUME 4 ISSUE 12 `200 INDIA MED TODAY
PERSPECTIVE: 2020
A YEAR OF UNPRECEDENTED CHALLENGES AND NEW LEARNINGS
DECEMBER 2020
INTERVIEW Jatin Mahajan, MD, J Mitra & Company
APPROACH We need these two policies to drive our recovery from COVID-19
OPINION MBBS Online
HEALTH-IT Lurking cybercrime in healthcare sector
EDIT NOTE www.indiamedtoday.com
December 2020 EDITORIAL Editor Neelam Kachhap
BOARD OF ADVISORS Dr Alexander Thomas Dr Girdhar Gyani
Sub-Editor
Dr Prem Kumar Nair
Sanjiv Das
Dr Bhabatosh Biswas
editorial@
Dr Alok Roy
indiamedtoday.com
2020: Year of Unprecedented Challenges and New Learnings
Ramesh Kannan
This year by far had been the most unexpected and eventful for us in the healthcare industry. That 2020 has been game changing for some is an understatement. How else do you
ART & PRODUCTION WepApp Logic Shylesh
CONSULTING EDITOR Dr Libert Anil Gomes Dr Salil Choudhary
ADVERTISING
explain the development of COVID-19 disease testing and management capabilities around the world. Thinking of the same time last year, as the curtain came down
Gunjan Chauhan
on 2019; can you think of even one moment that can be so life
gunjanc@indiamedtoday.com
altering? Who would have thought of this new and changed
The Media Ant help@themediaant.com DIGITAL MARKETING Vivek Nair Sales & Strategic Partnership Sujit Kaushik sujit.kaushik@indiamedtoday.com EDITORIAL ENQUIRIES editorial@indiamedtoday.com CUSTOMER SERVICE: Subscription support and other assistance for readers subscribe@indiamedtoday.com ADVERTISING ENQUIRIES sales@indiamedtoday.com OFFICE 301, Grazia, 1st main, 2nd Cross, Lingrajpuram, Bangalore 560084 www.indiamedtoday.com IndiaMedToday expressly disclaims liability for errors and omissions in this publication. While we try to keep the information timely and accurate, we make no guarantees. The views and opinions expressed in
world. Here we were on the cusp of the new decade, but instead of moving forward we just stopped. The world as we know it just took a break. The lockdown, travel restrictions and interrupted trade flow has impacted all of us. Be it a nurse, doctor or an administrative assistant, all of us have stories to tell. Some of these stories are scary, some reflect the never-ending endurance of the human nature but most of these stories are about kindness, hope and resilience.
Throughout, this year we have shared these amazing stories with you. We have kept you abreast with the daunting challenges our industry faced and the innovations that helped them. With this current issue we bring to you more such stories; experiences and learnings from industry leaders across India. We also bring you a comparative perspective on the vaccine development highlight for COVID-19 and a look at the policy initiatives that could help us get through post-COVID era. The next issue, Jan 2021, focuses on the challenges and learnings in the radiology and imaging world. Looking forward to the insights from world renowned radiologists and leaders and practicing radiologist in India who will outline the upcoming trends in this field.
the magazine do not necessarily reflect the official policy or position of IndiaMedToday or the publication. Information on IndiaMedToday should not be used as a substitute for professional healthcare advice.
Do write back and let us know your feedback.
Readers are advised to always seek specialist advice before acting on information contained in this publication. Never disregard professional medicaladvice or delay in seeking it because of something you have read on IndiaMedToday. No part of this publication or any part of the contents thereof may be reproduced, stored in a retrieval system or transmitted in any form without the permission of the publishers in writing. Printed and published by M Neelam Kachhap, 301, Grazia, 1st main, 2nd Cross, Lingrajpuram, Bangalore 560084 on behalf of Neelam
Editor M Neelam Kachhap
Publishing (OPC) Private Limited, Printed at Supriya Print Art 143, Pragati Industrial Estate, N M Joshi Marg, Lower Parel West, Mumbai - 400011. and published at 301, Grazia, 1st main, 2nd Cross, Lingrajpuram, Bangalore 560084.
www.indiamedtoday.com
3
DECEMBER 2020
CONNECT WITH US Join the conversation with IndiaMedToday through our social media pages Twitter
CONTENTS
12 16
44
INTERVIEW
OPINION
PULSE
Innovation and business foresight are important for the survival of any business
MBBS Online
Oxford-AstraZeneca Vaccine is Cheaper than Pfizer’s and Moderna’s and Doesn’t Require Supercold Temperature
18 COVER STORY
Perspective: 2020 A Year of Unprecedented Challenges and New Learnings
UPFRONT
03 Editorial 06 Letters 07 News roundup www.indiamedtoday.com
CHECKIT OUT ONLINE
www.indiamedtoday.com
5
LETTERS
A
ccording to the World Health Organization, currently, there are 422 million people battling diabetes globally, and India has the second-highest number of diabetes patients in the world. Treating diabetes requires a multidimensional approach. To prevent people from developing diabetes, it is crucial to inform the pre-diabetic population about the right lifestyle options to keep blood sugar, lipids, and blood pressure under control. This year, World Diabetes Day and Diwali fall on the same day. At Siemens Healthineers, we are making a conscious effort to support India's medical professionals, who call for a "Blue Diwali" to spread awareness on diabetes amidst the pandemic. With so many diabetics undiagnosed, understanding the risk factors, the symptoms, and the long-term impact is a crucial first step toward making communities in India and around the world healthier. Gerd Hoefner, Managing Director, President , Siemens Healthineers
India has a huge diabetes epidemic. The number of people with Type 2 diabetes is escalating in both the urban and rural areas of the country with almost 60% of Asians reported having diabetes or pre-diabetes by age 60. While we have seen a focused effort to teach people about Type 2 diabetes in the last few years, awareness about Type 2 diabetes or juvenile diabetes is still largely lacking. As a lifelong condition, families of affected children must be taught about daily glucose monitoring, timely insulin injections, and screening for complications. We should also counsel them on the psychological fallout and the need for emotional support. As it cannot be prevented or cured, the responsibility for educating families on the management of juvenile diabetes lies with the healthcare community and the government. This diabetes day we must also thank our nurses, who have been an essential part of our prevention and management strategies.
As the whole world is under the right grip of Covid 19, pneumonia
Dr Altamash Shaikh, Consultant Endocrinologist and Diabetologist, Saifee Hospital
Dr Vasunethra Kasaragod, Consultant Chest Physician, Vikram
has yet again attained the centre stage. Pneumonia is infection of the lungs and can be caused by various organisms that include viruses, bacteria, fungi and protozoan; the most common route of infection being inhalation. Patients have fever, cough with yellow or brown coloured sputum, breathlessness and tiredness as common symptoms. Early medical attention and diagnosis is imperative for early recovery. Patients are treated with antibiotics, oxygen and nebulisation most of the times. It’s more common among immuno compromised individuals like diabetics, chronic kidney and cardiovascular disease patients etc. Hence keeping these diseases under control is necessary to prevent pneumonia. Vaccination against flu and pneumococcus is helpful to prevent severe infections.
Hospital, Bengaluru.
FOLLOW US ON... @indiamedtoday facebook.com/indiamedtoday PLS ADDRESS YOUR LETTERS TO: The Editor, IndiaMedToday and mail to editorial@indiamedtoday.com Pls indicate clearly if you want to publish you views/opinions for this page.
6
December 2020
NEWS ROUNDUP One crore frontline healthcare workers to receive vaccine in first phase
Commission (UGC), according to the AYUSH ministry.
An estimated one crore frontline health workers will receive the first dose of COVID-19 vaccine whenever it becomes available, with around 92 per cent of government hospitals and 55 per cent of private hospitals across all states and UTs providing data identifying the workers, official sources told PTI. Five vaccine candidates are in advanced stages of development in India, out of which four are in Phase II/III and one is in Phase-I/II trials. States have been asked to accelerate the process of identifying frontline healthcare workers including doctors, MBBS students, nurses and ASHA workers etc, so that the exercise gets completed in another one week. It has asked states to do planning and mapping of vaccination sessions where healthcare workers will be vaccinated during the first phase and mapping human resources across departments that could be deployed for vaccination sessions for verification of beneficiaries, crowd management and overall coordination.
WHO to set up global centre for traditional medicine in India The World Health Organisation (WHO) will set up a Global Centre for Traditional Medicine in India. WHO Director-General Tedros Adhanom Ghebreyesus announced in a video message at an event in which Prime Minister Modi inaugurated two future-ready Ayurveda institutions in Jaipur and Jamnagar via video conferencing on the occasion of the 5th Ayurveda Day. The Institute of Teaching and Research in Ayurveda (ITRA), Jamnagar (Gujarat) and the National Institute of Ayurveda (NIA), Jaipur (Rajasthan) are both premier institutions of Ayurveda in the country. The Jamnagar institute has been conferred the status of an Institution of National Importance (INI) by an act of Parliament and the one at Jaipur has been designated an Institution Deemed to be University (De novo Category) by the University Grants
Manipal buys Columbia Asia lock, stock and barrel Bengaluru-based Manipal Hospitals based multi-speciality healthcare providers, today announced the acquisition of Columbia Asia Hospitals. The transfer of ownership to Manipal Hospitals is expected to be completed post regulatory approvals. This acquisition makes Manipal Hospitals India’s second-largest hospital chain after Apollo Hospitals. Post the deal, Columbia Asia will be rebranded as Manipal Hospitals. Columbia Asia Hospitals is part of Seattlebased Columbia Pacific Management, a private healthcare company owned by a US-based investment fund, International Columbia USA Columbia Pacific. The company has 17 hospitals in South-East Asia – 12 in Malaysia, three in Indonesia and two hospitals and a clinic in Vietnam and 11 hospitals in India. Manipal Hospitals will add these 11 hospitals to its existing hospitals to command strength of 27 hospitals across 15 cities with 7,200+beds, and a talent pool of 4,000+doctors and 10,000+employees.
Director General CSIR (Guest of Honour) also welcomed the startups, investors, panellists and other partners of the BIRAC’s innovation ecosystem.
Elekta appoints Gustaf Salford as President and CEO Gustaf Salford has been appointed to the role of President and CEO, Elekta, effective immediately. He has been acting CEO since early June 2020. “I am honoured to take on the role of President and CEO of this fantastic company. And I will, together with my team, accelerate Elekta’s strategy and future profitable growth. As the leader in precision radiation medicine we strive to increase accessibility to cancer care, build resilience and continue to push and expand the boundaries for innovation,” said Salford.
Sixth edition of BIRAC’s BIG Conclave held in Kanpur Biotechnology Industry Research Assistance Council (BIRAC) along with Startup Incubation and Innovation Centre (SIIC), IIT Kanpur recently organised the 6th edition of its annual flagship event BIG Conclave. The theme for this year’s two-day virtual conclave was ‘Resilience Redefined’ and has brought technical experts, global business leaders, innovators and entrepreneurs on a common virtual platform to unveil the innovations supported by BIRAC through its Biotechnology Ignition Grant (BIG) programme. The inaugural session of the event was graced by Jayant Sinha, Member of Parliament and former Union Minister, Government of India as the chief guest of the BIG Conclave 2020. Dr Renu Swarup, Secretary Department of Biotechnology, Government of India and Chairperson, BIRAC along with Dr RA Mashelkar, Former
Gustaf Salford
RDIF, Hetero to produce 100 million doses of Sputnik V vaccine in India The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Hetero, (through its biologics arm ‘Hetero Biopharma’) have agreed to produce in India over 100 million doses per year of the world’s first registered vaccine against the novel coronavirus infection – Sputnik V. The parties intend to start the production of Sputnik V at the beginning
www.indiamedtoday.com
7
NEWS ROUNDUP of 2021. Currently, Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India. Requests for more than 1.2 billion doses of Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
Rishihood University to launch School of Healthcare Rishihood University announced the upcoming launch of the Rishihood School of Healthcare. Considering the need, both at the national and international levels, the university is launching its School of Healthcare for its first cohort, from the academic session 2021-22 onwards. The School of Healthcare will be offering various UG & PG degree programmes, such as B.Sc. cardiovascular technology, medical laboratory technology, MBA in healthcare management, amongst others, under the allied healthcare domain. The courses have been designed to help the students to develop a high level of expertise and technical skills with detailed learning.
Rishihood University
8
December 2020
WB expands government health scheme Months ahead of the 2021 state polls, West Bengal Chief Minister Mamata Banerjee expanded the state-run ‘Swasthya Sathi’ health scheme to cover the entire population of the state. The decision will be applicable from December 1, 2020, Banerjee announced. “Earlier, we had decided to enrol at least 7.5 crore people under ‘Swasthya Sathi’. I am announcing today that every family in West Bengal, every person, be it a child or an old man or woman, irrespective of their religious affinity will be covered under this scheme,” Banerjee told newsmen. Every family will be provided with one smart card to avail the benefits of ‘Swasthya Sathi’ in which all state-run hospitals, as well as private hospitals in the state, have been roped in, she added.
AstraZeneca signs MoU with RSSDI AstraZeneca India (AstraZeneca Pharma India has signed a memorandum of understanding (MoU) with the Research Society for Study of Diabetes in India (RSSDI). This MoU is aimed at digitising
and driving correct awareness of diabetes amongst people to prevent complications arising from the uncontrolled incidence of the disease. RSSDI has been instrumental in extensive research on diabetes, as well as continuing diabetes education initiatives in India. As a key facet of this dual association, AstraZeneca unveiled a campaign-‘Beyond Sugar’, a three-year patient awareness programme developed to benefit over one crore people living with diabetes across the country. This initiative will empower patients/caregivers to have conversations around diabetes and make informed decisions about the management of the disease.
Lupin launches generic immunosuppressant drug in US Lupin has launched generic immunosuppressant Tacrolimus capsules in the American market after its alliance partner Concord Biotech received approval for the product from the US health regulator. The company has launched Tacrolimus capsules USP in the strengths of 0.5 mg, 1 mg, and 5 mg, after Concord Biotech received approval for its abbreviated new drug application (ANDA)
from the United States Food and Drug Administration (US FDA), Lupin said in a regulatory filing. The capsules are generic versions of Astellas Pharma US Inc’s Prograf capsules in the same strengths, it added.
Evercare Hospital Dhaka receives JCI accreditation
Evercare Hospital Dhaka, part of
important
collaboration
could
finally
begin. After successful training and certification
the Evercare Group is the first and only
of doctors and nurses at HCG Cancer
hospital in Bangladesh to be accredited by
Centre in Bengaluru in India, the team
Edelweiss Tokio Life unveils organ donation programme
the Joint Commission International (JCI)
treated its first patient after the lifting of
and also to be re-accredited for the fifth
the COVID-19 lockdown.
Continuing its social initiative #NoMoreWaiting for a second year, Edelweiss Tokio Life Insurance unveiled a unique educational programme on organ donation and a plan to build a corpus for underprivileged organ recipients. The insurer will continue its partnership with MOHAN Foundation, an NGO actively working for the cause. Once again, the insurer has roped in Rahul Bose, Actor and social activist, as the face of the initiative and aims to harness his social influence in spreading awareness for this cause. The 2nd edition of #NoMoreWaiting will extend for a year and aims to create organ donation ambassadors across the country through a structured programme. As a part of this programme, the insurer, together with MOHAN Foundation, will offer a 4-hour online certification course, followed by a 2-hour interactive session with experts, organ donor families and recipients.
recognised
time in a row. The JCI Gold Seal of Approval is a globally accreditation
that
reflects
an organisation’s commitment to best practices in quality and patient safety. Accreditation by recognised international institutions such as JCI is crucial to drive
Govt allows Ayurveda practitioners to conduct surgeries
Government of India in a recent
notification
has
allowed
postgraduate
compliance and improve quality and cost
degree holders of Ayurveda to perform
effectiveness across the hospitals and
general
accreditation has become a priority for
orthopaedics and dental procedures. A
healthcare organisations around the world.
gazette notification dated November 19,
ChemoTech initiates collaboration with HCG
2020, by Central Council of Indian Medicine
Scandinavia-based
ChemoTech
such procedures. The notification further
and HCG have engaged in an agreement
stated that the amendments were being
Electroporation). The evaluation is led by HCGs Department of Translational the
training
ophthalmology,
pass outs to receive formal training for
IQwave and the TSE (Tumour Specific
After
ENT,
(CCIM) allowed Ayurvedic post graduate
to perform a scientific evaluation of
Medicine.
surgical,
and
made with the sanction of the central government. Students will be trained in two streams of surgery and would be awarded titles of MS (Ayurveda) shalya
certification of doctors and nurses that
tantra general surgery and MS (Ayurveda)
took place in early November at HCG’s
shalakya tantra (disease of the eye, ear,
cancer centre in Bengaluru India, this
nose, throat, head and oral dentistry).
www.indiamedtoday.com
9
NEWS ROUNDUP The Hague Business Agency launches digital programme at Bangalore Tech Summit The Municipality of the Hague and the Department of IT, BT, Government of Karnataka have been working together under the broad MoU that was signed between the two sides in 2016. Taking the collaboration forward, The Hague Business Agency launched a digital softlanding programme, aimed at Indian startups looking for expansion into Europe, at this year’s Bangalore Tech Summit. Key dignitaries at this year’s event were Saskia Bruines, Deputy Mayor of the Hague, Jeroen Tas, Chief Innovation Officer at Royal Philips and Gert Heijkoop, Consul General of the Netherlands in South India. Through this programme, 50 Indian tech startups active in areas such as AI, cyber security,
agriculture,
healthcare,
and
smart cities will be selected for digital soft landing in the Hague. It will be a two-month online programme, which will consist of following four steps: Explore: Digital Fact-Finding Trip; Adjust: Market readiness training; Connect: Match Making and Integrate: Ecosystem integration, for Indian startups to get fully immersed into
Ratan Tata invests in healthcare startup iKure Healthcare services startup, iKure said veteran industrialist Ratan Tata has invested in the company an undisclosed sum. The company, which delivers primary healthcare services through a network of clinics, digital technologies and trained frontline health workers, said it plans to rapidly scale-up operations across India and globally with fresh funds coming in.
December 2020
is a part of the overall strategic plan of value creation for our shareholders through Biocon Biologics.”
Dr Prasanna HM takes charge as President of PHANA
Dr Prasanna HM has taken charge
Biocon Biologics receives $150 million capital from Goldman Sachs Biocon announced that the Board of its subsidiary Biocon Biologics Ltd (Biocon Biologics) has approved a Rs 1,125 crore (~$ 150 million) capital injection from Goldman Sachs. As per the terms of the proposed agreement, Goldman Sachs will be issued optionally convertible debentures at a post-money equity valuation of $ 3.94 billion. The transaction is subject to customary approvals and conditions.
of family and welfare, Dr R Ravindra,
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said, “We are pleased to welcome a capital injection by Goldman Sachs at this inflexion point of Biocon Biologics’ journey in its quest for global
SCHOTT Glass India inaugurates new glass melting tank in Gujarat
10
through biosimilar drugs. This transaction
as the President of Private Hospitals and
the Hague ecosystem.
SCHOTT has inaugurated a new melting tank in its Gujarat-based facility with an approximate investment of EUR 25 Million. The new tank would help to increase the plant’s production capacity by 10,000 tonnes to reach an annual capacity of 40000 metric tonnes. SCHOTT has been a frontrunner in the global fight against Coronavirus, with a commitment to provide its specialised pharma glass used for storing billions of COVID-19 vaccines. The melting furnace has been constructed within one year, to enable a 25 per cent increase in the facility’s overall production capacity, to support the pharma industry that is facing a huge demand surge for pharma packaging products.
leadership in providing affordable access
Dr Prasanna HM
Nursing Homes Association (PHANA). Chief Guest Jawaid Akhtar, Principal Secretary to Government of Karnataka, Department Past President, along with Dr Prasanna, office bearers, guests and dignitaries were present on the occasion. While addressing the august gathering and media, incoming President Dr Prasanna requested the government to release the payments to hospitals for treating COVID patients.” He further requested the government for SME stimulus to help struggling hospitals, besides ensuring the release of GOI insurance to a family of COVID warriors in the private sector who lost their lives.
Fortis re-appoints Dr Bishnu Panigrahi Fortis Healthcare announced that Dr Bishnu Panigrahi has re-joined the company as Group Head, Medical Strategy and Operations to make a more substantial contribution to the patient care and clinical excellence parameters. In his earlier stint, Dr Panigrahi spearheaded medical operations at Fortis Healthcare from January 2012 to August 2018. He was instrumental in making Fortis, the destination of choice for those seeking medical services in India. Dr Panigrahi has an experience of 39 years out of which 12 years was as an educator and 27 years was in the corporate world where he worked with Indraprastha Apollo, Fortis and Max Healthcare. Before rejoining Fortis, he was associated with Kalinga Institute of Medical Sciences (KIMS), Bhubaneswar as Chief Executive Officer.
decades of experience in healthcare IT solutions and services, working in high growth technology-led businesses. His appointment is a strategic move for Aetna India to build on the success of the last few years and continue to develop the company. Khosla will oversee all aspects of India business which caters to over 4 million members.
limited to, the design and implementation of multiple pivotal Phase 3 trials to enable
regulatory
submission,
review,
and, if supported by data, approvals for the use of Avigan tablets in the treatment or prevention of COVID-19 in the US, Canada and internationally. The clinical development strategy will focus on evaluating Avigan tablets for early treatment and post-exposure prophylaxis in the community setting.
Dr S Rajasekaran bags Stanford University’s recognition Stanford recognised
University
group,
orthopaedic
USA,
surgeon
has Dr
S
Rajasekaran for his contribution in the field of orthopaedic surgery. His name has been categorised as the top 2 per cent of scientists whose work has had the maximum impact in their respective fields. The authors also refined the method of analysis by excluding self-citations. For each author, separate data for career-long and the single-year impact was calculated. Metrics with and without self-citations and ratio of citations to citing papers
Anurag Khosla
Appili Therapeutics Dr Reddy’s, GRA, FUJIFILM in tie-up
Aetna India appoints Anurag Khosla as CEO India
has
announced
22 scientific fields and 176 subfields. Field & subfield-specific percentiles were also provided for all scientists.
Appili Therapeutics has signed a collaboration, development and supply agreement with Dr Reddy’s Laboratories and Global Response Aid (GRA). This agreement follows on and is harmonised with the previously announced global licensing transaction (excluding Japan, Russia, and China) between DRL, GRA and FUJIFILM Toyama Chemical Co, (FFTC), the originator of Avigan tablets. The agreements work together to coordinate and accelerate the worldwide development, commercialisation, and distribution of Avigan tablets (favipiravir) for the potential treatment and prevention of COVID-19.
Dr Bishnu Panigrahi
Aetna
were done. Scientists were classified into
the
appointment of Anurag Khosla as the new Chief Executive Officer to accelerate its business in India. Khosla brings in two
Appili will assume key responsibilities for the design and implementation of the consortium’s global clinical programmes and related work, including, but not
Dr S Rajasekaran
www.indiamedtoday.com
11
INTERVIEW
Innovation and business foresight are important for the survival of any business Jatin Mahajan, Managing Director, J Mitra & Company talks about the key learnings from the COVID-19 pandemic, the challenges faced at the company's manufacturing unit and the way forward in 202, with M Neelam Kachhap How did the COVID-19 pandemic affect medical device manufacturing? The initial two to four days of the lockdown were very difficult and challenging. Everything came to a standstill. The manufacturing units were closed; staff and workers were unable to reach offices and and essential supplies were completely disrupted. While we fall under the essential services category, and therefore exempt from the restrictions, we had to arrange passes for our staff, and in the ensuing chaos and melee, this took a lot of time and energy.
December 2020
Another key impact was the overall negative sentiment created – the fear created because of the corona pandemic created an environment of fear and mental stress for all, impacting workers morale which had a direct bearing on attendance as well as productivity. The most critical challenge that continues to
plague
the
diagnostics
industry,
especially concerning COVID-19 testing
All forms of transportation and logistics were severely affected. Raw materials in transit were held up along the route. No new orders for raw materials could be placed in the embargo situation. So, we were forced to handle the double whammy of human resource crunch and supply-side stress – the two most critical aspects for any manufacturing unit. Also, the scenario created a reduced cash flow and liquidity issue which is very detrimental for the smooth functioning of any industry.
has been the export embargo that has
What were the challenges faced by the medical devices business?
production and related costs, and then
Unlike us, most players in the medical devices industry heavily bank on import of raw materials from abroad. The logistics and import-export embargo created an immediate flux for the industry – a scenario where they did not have enough raw material to sustain production.
12
The prevailing inverted duty structure favoured finished products (imported IVDs) over raw materials (made in India IVDs) – consequently leading to an unequal playing field for all domestic producers of IVD devices.
been imposed by the government on Indian manufacturers. There is sufficient manufacturing capacity within the Indian medical
devices
manufacturers
for
COVID-19 test kits to cater to the domestic demands.
The
government,
however,
continues to source from international manufacturers, creating a situation of surplus stock for all Indian manufacturers. We
are
being
forced
to
undertake
sell in a restricted market. We are being forced to store these finished products which in many cases require a specialised temperature-controlled environment. This negatively impacts the shelf life and leads to a situation of near-expiry for the kits which affects the pricing and sale-ability of the products. This is severely hurting the bottom-line of the entire industry and needs to be addressed urgently.
Could you tell us about the innovations during this time? Innovation and business foresight are important for the survival of any business. Innovations do not necessarily have to be technical – it could be in the overall work and management style itself. While we were not majorly impacted, we could see many industry counterparts struggling to maintain business continuity because of their over-dependence on China for raw materials. A robust business continuity plan is a must to mitigate the negative impact of large-scale disruptions. Flexibility
and
adaptability
must
be
incorporated in the business ethos. But most importantly, while we may be a for-profit organisation, we have learnt the most critical aspect is humanity, compassion and social consciousness. It was critical to creating an environment devoid of fear, and as a company, we were able to create that mindset for the staff at work. We were able to keep the motivational levels high by meeting all legitimate financial needs while providing the
safest
and
most
sanitised
we
understood
work
environment As
a
company,
the
significance of human qualities as a driving force for professional and technical qualities which contributed to keeping the entire team together. Together, as a team, we went ahead to innovate and create/manufacture two of the best Covid-19 test kits – • COVID-19 [IgM, IgG, IgA] MICROLISA Our state-of-the-art test kit based on the Double Sandwich Elisa technology is a serology-based total antibody (IgM, IgG, IgA) detection assay for the indirect diagnosis of past exposure to COVID-19. It has a sensitivity of 94.04 per cent and specificity of 100 per cent. • J Mitra also manufactures the ICMRNIV developed COVID KAWACH IgG MICROLISA COVID-19 test kit which tests for IgG antibody in human serum/ plasma and has a sensitivity of 96.33 per cent and specificity of 100 per cent
Jatin Mahajan, Managing Director, J Mitra & Company
How are things currently?
the diagnostics industry. Being a leading
At J Mitra, things are almost back to normal. The production of the two COVID-19 test kits has kept us busy, in addition to the other test kits that we manufacture.
are likely to enjoy a sizable chunk of the
The current scenario has drawn a lot of focus on the healthcare industry and its contribution. Its criticality and yeoman services are being re-established, recognised and appreciated. The world recognises the need for early warning systems in the healthcare segment, especially for COVID-19. There is an expectation of phenomenal growth for
government lifts the embargo on exports
exporter of IVDs to the global market, we global buyers seeking these test kits apart from our other existing product lines. But this will only be possible if the Indian of COVID-19 test kits.
How do you see the situation improving in the next year? India is the third-largest producer of pharmaceuticals
and
related
products.
www.indiamedtoday.com
13
INTERVIEW The country has the potential to become the alternative supplier to global drug manufacturers replacing China due to growing distrust and possible sanctions. There is a possibility of the world focus shifting to India as the primary producer and supplier of APIs, IVDs and generic drugs, provided we act fast. The Centre has taken cognisance of India’s potential and need for self-sufficiency in APIs, IVDs and generic drug segment. The Central Government is actively looking at various possibilities and opportunities, and if all goes well as envisaged, India could end up being a major winner from the corona disaster. Recent developments indicate a concrete step in the right direction. • Government announcement of Rs 140 billion fund for the establishment of three drug manufacturing hubs • Government allocation of Rs 3,000 crore to promote bulk drug parks in India along with a production-linked incentive scheme of Rs 7,000 crore •
The government has identified elements and APIs which will the initial thrust in phase 1 of government planning and will promoted on priority
53 be the be
The Indian government recognises aspects critical for winning this race – ensuring a cost advantage over China, faster government permissions and single-window clearances, ease of doing business, adequate financing, competent infrastructure, soft loans with longer repayments – these are aggressively being looked at.
14
December 2020
Speed is critical – If India has to succeed in capturing a significant portion of the market up for grabs, they have to display aggression and garner the first mover’s advantage.
What are your recommendations for the future? Yes, there are some key aspects that I would like to communicate with the policy-makers. There is a need to cut down import duty on raw materials and hike import duty on finished goods, which is the lowest in India amongst the BRIC countries. This is very critical. Just to cite an example, ELISA finished products (HS Code – 38220019 List 4 Sr. No. 32) have 0 per cent duty and 5 per cent IGST, whereas the raw material for ELISA kits under the same HS code attract 5-20 per cent import duty plus 12 per cent IGST – creating a price differential of 2025 per cent, and tilting the balance away from the home-grown manufacturers. Aspects critical for winning the Make-inIndia race are – ensuring a cost advantage over China, faster government permissions and
single-window
clearances,
ease
of doing business, adequate financing, competent infrastructure and soft loans with longer repayments. Other
key
governmental
focus
areas
should be – the creation of large clusters with a common infrastructure, facilities and subsidies for technological upgrades so that there are higher sustainability and economies of scale.
www.indiamedtoday.com
15
OPINION
MBBS Online What are the challenges faced while teaching medical students virtually The medical education sector like other
the readers about some of the challenges
sectors has been hugely impacted by
which I faced while teaching via the online
the
mode.
COVID-19
pandemic.
Conducting
regular classes and examinations came to a standstill amidst the lockdown and professors and students alike are grappling with the new set of challenges. At normal times a first-year MBBS student invests more time in learning about human
Dr Ashish Banerji Seasoned Healthcare Administrator
anatomy, physiology and biochemistry. Anatomy is learnt in classrooms (through didactic lectures), but a large part of the learning
message the moment it happens), and then rejoining when he/she is able to reconnect. This is extremely disturbing for a teacher, and the students too, as they miss a few The process of leaving the online class (so and so has left) and rejoining goes on
In
MBBS
throughout the lecture. Apart from this,
students examine real patients, who have
the teacher is unable to see any of his
'complaints,' and work on the case history
students. There is no choice but to assume
while examining to elicit findings. All this
that those who are electronically present
is done under the supervision of doctors.
(having logged in) are paying attention. It’s
Students present cases to their fellow
quite likely (and possible) that students
students and a staff member corrects in
may be busy with their cellphones or doing
case of any errors while enquiring more
some other activity altogether. I am saying
about the topic. These are also known as
this because even in classroom teaching, a
bedside clinics.
few students are inattentive and are busy
A similar procedure is also followed for
ask random questions, and although this
post-graduate students pursuing a PG
helps, a large number of students make it
degree in a clinical speciality: lectures,
difficult to implement.
presentations
third-year,
browsing with their cellphones. One can
and
discussions.
Surgical residents across all specialities are taught surgical techniques by observation, assisting
senior surgeons,
then
doing
simple surgeries under their supervision and finally operating independently.
December 2020
by without students 'leaving' (you get a
assigned a 'body' or a 'part' to dissect.
case
16
I would say that not a single lecture goes
minutes or a large portion of the lecture.
and
dissection
all too true!
where a group of six to eight students are
second
in
technical glitches,' and this is unfortunately
halls,
the
happens
I was warned that there would be 'some
What happened to 'bedside clinics, which is one of the most important methods of teaching? This mode of teaching is currently being conducted online where one student examines the patient (others can do it at different times), and he/she
Since the onset of COVID, all this has
presents the case to other students and
drastically changed. Everyone I spoke
the teacher virtually. The correct history
to said that didactic lectures which were
(complaints with duration) and physical
taken in large lecture halls, (student
findings are conveyed to the professor
numbers could be as high as 250 in a batch)
by a junior doctor in the department. The
have completely stopped. Now teachers
student who is presenting the case shows
have adopted the virtual mode of teaching
the relevant investigations like ECG, X-ray
and students have to log in and learn by
Chest, CT scans, MRIs etc to everyone using
this modality. While it may appear to be a
his/her cellphone. The entire process can’t
satisfactory method, I would like to inform
be compared to pre-COVID era teaching,
but it’s the best solution, given social distancing norms to be followed.
mode is not possible. All these problems are formidable and
Conducting exams is another challenge.
medical colleges are grappling with them.
Exams in medical colleges are conducted
New admissions are not yet done and are
in three formats. The theoretical paper usually has subjective questions with a few
overdue. NEET exams have been delayed.
short notes. Online examinations can lead
Deployment of junior doctors, often doing
to mass cheating. In most medical colleges
post-graduation, has been a subject of
students are being allowed to sit in large
intense debate. Due to the incessant
halls, ensuring social distancing, utilising
demands of residents to man the COVID
20 to 25 per cent of the hall capacity.
wards
Strict invigilation ensures no unfair means,
confirmed COVID cases), many hospitals
although I recently heard about mass-scale
have had to resort to deploying PG
cheating using technology similar to that shown in the movie Munnabhai MBBS, but in a more sophisticated way. The
second
(for
suspected
and
doctors pursuing 'non-COVID' specialities in such wards. The reason behind this was that internal medicine and chest medicine departments are unable to fill in
presentation, which can’t be conducted
all the required slots. Here, I am referring
online, as the examiners have to examine
to specialities like ophthalmology, ENT,
the
orthopaedics etc. While hospitals have
and
is
ICUs
case
patient
modality
and
converse
the
with
both
the student and the patient. It is being conducted by maintaining as much social distancing as possible, but it possesses definite challenges. The third modality is drugs, specimens and instrument tables, where the examinee is shown various drugs, surgical specimens of
realised that it is unfair, inappropriate, to deploy doctors doing PG in such disciplines in COVID wards, they often have no choice. The overall teaching in medical colleges is mired with challenges. Imparting medical education, at all levels, and managing
diseased organs (removed from patients)
COVID patients, still continues to throw up
and equipment, Here the student has to
complex challenges, which administrators
answer questions about usage of the drug
are finding solutions for. There can be no
or equipment, surgical instruments (for
doubt that the students of medicine will be
surgical disciplines). In this case, online
impacted, at least, in the short term.
www.indiamedtoday.com
17
COVERSTORY
Perspective: 2020
A Year of Unprecedented Challenges and New Learnings
What does the future hold for the healthcare sector? 2020 has been an adversary not many could handle and yet it forced us to look for opportunities and ways to innovate and raise up to the challenge that the pandemic brought with it. We round up the best experiences and advice from industry thought leaders to lead you through the new normal. In this year-end issue of IndiaMed Today, healthcare experts talk about the flaws in the system which need to be looked upon, ways to overcome the challenges by implementing the right decisions, economic revival for the sector and the way forward in 2021. Team IMT
18
November 2020 December 2020
Dr Alok Roy Chair, FICCI, Health Services Committee, Chairman Medica Group of Hospitals
COVID-19 has been undoubtedly the
We need to create a flexible workspace in the hospital and to fit the hospital in retrofit or forward format where we can change the settings in as short a period as possible
most devastating public health emergency in the last century. It reminded the entire generation that we are mere pawns in the hands of nature. Being in healthcare, we have earned the epithet, frontline warriors, deservingly so. As health workers, we must serve the society at large. As caregivers, we are learning on the job, as no classroom theory could have helped us break the shackles of the virus. The pandemic has made us better at learning on the go. Private healthcare services, which have long been neglected politically have risen to the occasion to save the populace. With nearly 80-90 per cent of COVID patient care being provided by the private sector, we have accepted this untimely challenge and taken it head-on, ably supporting public healthcare at large. Some of the major learnings are to not take life for granted. We must all learn to be flexible and engage the pandemic on the front foot. Hospitals across the country did this over the last few months. Another key learning is that in India, about 86 per cent of patients are asymptomatic or mildly symptomatic. We are dealing with the remaining moderate to severe patients who need hospital care. Over time, we have learnt, adapted and become extremely skilled at ICU patient care. With no clear evidence and strategies for ICU care at the beginning of the pandemic, our experiences have taught us well. The Indian healthcare system was not well equipped to deal with a pandemic of this nature, so we redesigned our infrastructure, treatment protocols and processes. This allowed us to protect our employees as well as the COVID and non-
COVID cohort of patients. Healthcare has undergone a 360-degree transformation while fighting COVID-19. The healthcare sector has taken a massive financial hit and for healthcare to emerge strongly from this crisis, the health budgets need to be substantially upgraded. India’s public health expenditure stood at 1.15 per cent of its gross domestic product – this must take a quantum leap and must be more than doubled to reach the goal of 2.5 per cent set by the National Health Policy 2017 while being further increased to 3 per cent4 per cent of the GDP in the medium term. Health and wellness have been severely impacted by the ongoing pandemic. Hence, in looking at health, and its future trends post the pandemic, we will take a more holistic approach to the healthcare scenario. We will also look at influencing factors - especially macro factors like the higher likelihood of impact on the older and ageing population, increase in chronic diseases and co-morbidities, rising health care costs and enhanced demand for product transparency. We have to adapt to the new normal. The new normal is that we have to rely on technology, the digital platforms. We need to create a flexible workspace in the hospital and to fit the hospital in retrofit or forward format where we can change the settings in as short a period as possible. In the new normal, we need to have lesser beds in larger spaces. The more we space out the bed it will probably change the way. Also, we need to invest in technology in big time. We need to think that these things can occur and prepare for such things and invest more in public healthcare.
www.indiamedtoday.com
19
COVERSTORY MR Rajgopal Founder & Chairman, Pallium India
I must admit this; we were afraid. It was
little about treating physical symptoms
partly the fear of the unknown; a disease
nor about the enormity of the psychosocial
about which we knew little and about
suffering. Will we recognise healthcare
whose treatment we knew even less. We
for what it should be and make sure that
were afraid for our patients who all have
the healthcare system includes enough
comorbidities. The patients and families
professionals trained in palliative care and
were afraid too. Many asked us to stop
psychosocial work?
visiting them at their homes; we were seen as carriers of the disease.
Ata Declaration of 1978 asked and what
course of our work and risking our families’
the Astana Declaration of 2018 reinforced.
Community Engagement
20
December 2020
need to put into practice what the Alma
We were afraid of getting infected in the lives.
The first is the need to make healthcare what it should be, health being defined as physical, social and mental well-being and not just absence of disease or infirmity
Our COVID experience also highlights the
We could no longer think about looking
Healthcare has to involve the community professionals and the community working in partnership.
after only 'our patients' – people registered
And let us hope that healthcare systems
with us. We announced a helpline in
can perceive the mountain of suffering
the newspapers, offering help to those
caused by the inequities in society. The
who needed it and asking for volunteers
vulnerable population suffered enormously
between the age of 20-40 who owned their
not only from COVID-19 but also from
automobiles.
the lock down. The inequity is something
Would the world order change and society
that happens in the invisible recesses of
with compassion emerge as a response
our society - invisible to those who are
to the catastrophic 2020? Let us hope it
in power. Those with disabilities, those
does; but the experience from the plague
geographically,
epidemic of long back tells us that while
isolated, those at the extremes of age - all
some may change, human nature will
have suffered to an unbelievable extent as
prevail.
in any humanitarian crisis.
There certainly are lessons to be learnt
“The moral test of a society is how that
from what we have gone through in 2020.
society treats those who are in the dawn
The first is the need to make healthcare
of life...the children; those who are in the
what it should be, health being defined as
twilight of life...the elderly; and those
“physical, social and mental well-being and
who are in the shadows of life...the sick,
not just absence of disease or infirmity”.
the needy, and the handicapped” (Hubert
Global healthcare systems have bothered
Humphrey).
socially
and
culturally
www.indiamedtoday.com
Dr Alexander Thomas President, Association of Healthcare Providers – India (AHPI)
Reduced manpower has made hospitals rethink to focus on multitasking as well as to explore new technological solutions to improve the efficiency and enable staff to operate safely
The COVID-19 pandemic has become a
Healthcare workers faced challenging times
major global threat globally which has
directly catering to COVID-19 patients.
impacted the economies and livelihood of
They are overworked, which makes them
people. The private hospitals in India played
vulnerable to errors and possibly increases
a huge role in tackling the virus while
their risk of getting infected. Compounding
stepping up operations to complement and
this is the fear and mental exhaustion from
enhance the efforts of the government.
overwork, death of patients, colleagues
Many private hospitals allotted extra beds
falling ill or dying from the infection, and
and additional manpower, set up isolation
their safety. Also, healthcare workers got
wards, brought in new equipment, set
separated from their family members for
up the desired inventory and converted
a long time as many opted not to visit
their premises into COVID care and hybrid
their homes fearing infection risk to their
facilities, to ensure that other medical
families. All these took a heavy toll on
emergency needs are not compromised.
them. Hospitals have adopted new working
Though a lot of initiatives have been
social distancing at work, communicating
undertaken by the private hospitals, poor
through phone calls, instant messaging,
patient
of
conference calls and emails have become
elective procedures have led to reduced
the new norm. Cross-functional task forces
financial inflow to about 30 per cent.
are formed. Reduced manpower has made
As a fallout, hospitals in many instances
hospitals rethink to focus on multitasking
were unable to pay salaries to their
as well as to explore new technological
employees, found it difficult to meet the
solutions to improve the efficiency and
EMI requirements and annual maintenance
enable staff to operate safely.
footfall
and
postponement
mechanisms during COVID times. Practising
contracts. Private
Ever since the threat of COVID-19 crippled hospitals
were
functioning
our country, AHPI has been at the forefront
with 20 to 30 per cent of the capacity.
working closely with the central and state
Postponement of elective surgeries, dip
government in preparing and implementing
in footfalls, reduction in OPD patients,
ways to tackle the crisis. AHPI worked with
complete halt on international patients due
the governments, and this has led to many
to travel ban and a significant fall in bed
suggestions offered by AHPI being accepted
occupancy and inpatient treatments have
and implemented. The members of AHPI
had an impact on the revenues significantly.
continue to hold regular meetings with all
Besides increased input costs resulted in
state chapter office bearers as together we
huge losses across hospitals.
face this unprecedented challenge.
www.indiamedtoday.com
21
COVERSTORY
Dr S Prakash Managing Director, Star Health and Allied Insurance Co
The realisation of the need for insurance protection is now very well understood, however, availability of surplus money in the hands of industry or individual is prerequisite for growth of insurance
Lockdown and COVID-19 have given
insurance.
rise to a golden era for health insurance.
concept was introduced in 1997, it was felt
No amount of effort put by a regulator or
that in a family only one or two may get
insurance companies would have created
hospitalised during the year and the floater
such an amount of awareness among the
sum insured is sufficient to take care of
general public on the need and requirement
their hospitalisation. Now COVID-19 has
of health insurance which is now created by
made them think otherwise as the entire
COVID-19. This impact is not a short-term
family was required to get hospitalised
impact as it has changed the mindset of
and sum insured under floater policy
people. Health insurance is now purchased
found to be inadequate. This has given
for its real purpose i.e. financial protection
rise to the purchase of additional policies
at the time of need. When any insurance
or top-up policies to take care of likely
is purchased as a real financial protection
huge
law of a large number will work and the
insurance premium figures for the first half
probability of loss gets limited. Otherwise,
of this financial year reflects the impact
health insurance is purchased only when
of COVID-19 on health insurance. Though
there is an adverse health history where
the overall growth in health insurance
the probability of occurrence of loss is
premium is only 16 per cent, retail health
much higher. We have been requesting
insurance has shown the growth of 26 per
our marketing team to sell policies of
cent and Company like Star Health has
the higher sum insured but they were
shown growth of 48 in the retail segment.
reluctant. Now the same marketing persons are vehemently pitching for policies with higher sum insured. The real meaning of adequacy of sum insured is understood by an insured when he gets to know from social media about huge hospitalisation bills for COVID-19 treatment in hospitals. Concept of health insurance marketing has changed, people with the age group of below 45 were reluctant to go for health insurance but now COVID-19 made them
22
December 2020
Similarly,
hospitalisation
when
the
expenses.
floater
Health
Another most important aspect of lockdown and COVID-19 is forcing the industry to adapt to work from home culture and optimum use of technology. Pre pandemic, online sale of health insurance was only around 4 to 5% and now it has gone up to 80%. This aspect will make the company think about structural change in their set up which in turn, will substantially reduce the operating cost of the company.
realise that age has no bearing when it
The health insurance industry will have
comes to COVID and made them buy health
to take this challenge very seriously and
consider this as an opportunity. There is huge untapped potential available, as on date 86 per cent of the rural population
take health insurance to the next level. Pandemic has temporarily impacted the
The realisation of the need for insurance protection is now very well understood,
insurance industry as every economic
however, availability of surplus money
activity was standing still for some
in the hands of industry or individual
time, however, it will bounce back with
is a prerequisite for the growth of
vigour during the next financial year.
insurance.
the survival of the health insurance
We
the
Barring unexpected situations, we can
industry is more dependent on claims
economy during the last quarter of
assume that the economy will bounce
servicing.
this FY, with vaccination for COVID-19
back during the next financial year,
coming in the market, the economy
all
and 81 per cent of the urban population is without any insurance protection and with this background, we can conclude that potential is unlimited. However,
There
is
a
huge
opportunity
for
innovation of disease based policies
will
are
see
expecting
stability
exhilarated
growth
in
which
pending
infrastructure
projects,
industrial activities will be expedited.
and policies for uncovered medical
automatically can help the insurance
expenses In reality on an average every
industry
to
person is spending about 5 per cent of
casualty
and
is
area of operation both in marketing
his income on medical expenses during
directly linked to the growth of the
and servicing will be taken as a priority
the year. Insurance companies will have
economy. Similarly with the growth
by every insurance company. As the
to find a way out to provide cover for
of the economy, spending capacity of
rural economy is growing very fast and
these expenses.
public will increase and in turn, health
urban workforce have started migrating
insurance is likely to get the maximum
to rural areas due to the introduction
benefit out of this.
of remote working culture, we can see
diagnostic
Next year will be a golden year for the
huge potential for insurance marketing
laboratories etc., will go a long way to
insurance industry, be it life or non-life.
in rural areas.
Similarly, enduring relationships with various
stakeholders
technology
like
partners,
hospitals,
grow. auto
Both
property/
insurance
Extensive use of technology in every
www.indiamedtoday.com
23
COVERSTORY
Aditi Kare Panandikar Managing Director, Indoco Remedies Limited
We believe the Indian pharma industry can utilise this crisis of COVID-19 as an opportunity to reframe its global commitments and emerge as a significant player and associate with a large developing market
24
December 2020
The COVID-19 pandemic has created an
act and adapt and tackle the challenges
unprecedented disruption and impacted all
efficiently.
businesses globally. The lockdown across
Despite many odds, our company took all
countries created a negative impact on
efforts to ensure continuity in operations
the GDP, leading to a global recession. The
and supply chain, both in India and
pandemic also had major effects on the
across the world, with all the safety and
healthcare and pharma sectors. Before
precautionary measures. Indocoites across
COVID-19 also, the overall economy was
various locations rose to the occasion,
facing headwinds both domestically and
braving the risk and hardships in reporting
in key global markets. Nonetheless, many
to work, whenever possible or contributing
opportunities exist across geographies and
in a meaningful way by working from home
product classes for Indian pharmaceutical
(WFH).
players to serve the patients across the
Indoco was part of the great initiative
globe.
by
The pharma industry joined the team of the medical fraternity, the doctors, nurses, medical staff, government authorities, etc., and worked relentlessly and selflessly to keep everyone safe and spread awareness on the pandemic. While currently there is no definite treatment or cure for this
the
Indian
government
to
export
paracetamol tablets to the UK in its fight against COVID-19 and was granted permission to airlift paracetamol tablets to the UK. The first shipment of paracetamol tablets manufactured at our plant was airlifted from Goa airport on April 12, 2020 by a chartered flight for export to the UK.
infectious disease and the research for
India is one of the largest producers of
the vaccine is still on, the pharmaceutical
anti-malarial
industry has provided constant assistance
This was used in the treatment of COVID-19
to the government authorities to address
during the initial phase of the pandemic.
the unmet needs of the patients by making
India sent the drug to over 50 countries,
drug
hydroxychloroquine.
medicines available at affordable prices. It
including the US.
has been impressive to see how fast the
Many pharma companies developed and
industry responded to the outbreak. This
launched Favipiravir, an oral antiviral drug
shows the industry’s resilience to quickly
approved for the treatment of COVID-19
has been safe and effective in treating
In the wake of new challenges, several
mild to moderate cases. Treatment
different approaches were taken by
with this drug has led to significant
Indoco to create multiple touchpoints
improvement in the time taken for the
with
infection to be cured.
mode was effectively utilised to reach
Indoco was already in the prevention of COVID-19 with its brands, Karvol Plus, ATM (Azithromycin), Febrex Plus & Rexidin SRS and is now in the treatment of COVID-19 with the introduction of Fevindo (Favipiravir) 400 & 800 mg tablets, Poviclean Gargle & Zmun CD Chewable Tablets (Immunity Booster with Vitamin C, Vitamin D3 & Zinc). The company wasted no time in adopting measures to protect the health of its
various
stakeholders.
Digital
and connect with all key stakeholders like
doctors,
retailers,
stockists,
as
well as our overseas customers. Our objective was to build a much more engaging suite of virtual interaction models, e.g., care-delivery adaptation, patient-support supply-and
enhancement
and
inventory-management
innovation. This paved the way for a greater spirit of partnership. We believe the Indian pharma industry can utilise this crisis of COVID-19
employees and ensure the business
as
continuity
global commitments and emerge as
with
minimal
disruption.
an
opportunity
to
reframe
its
Except for the initial few days of
a
the lockdown, all our manufacturing
with
facilities were kept operational. To
India’s and the world’s fight against the
overcome
the
manpower
significant a
large
player
and
developing
associate market.
shortage,
deadly COVID-19 is still on and we are
the company recruited over 350 new
sure that this phase too shall pass and
employees across various locations and
we shall come out stronger from this
in the field during this pandemic.
crisis!!!
www.indiamedtoday.com
25
COVERSTORY
Dr Naresh Shetty
President, M S Ramaiah Memorial Hospital
The
lock
down
COVID-19
constant counselling, which is not only
pandemic has taken a toll on the operations
physically taxing but a huge mental health
of
20
burden. Shortage of PPEs, high cost of
per cent occupancy and salaries to be
masks and PPEs, shortage of essential
paid, it has never been so bad. Even the
drugs and sourcing them remained a major
government on certain occasions put forth
challenge. In worst-case scenario unused
terms where hospitals were told to admit
PPEs were disposed of without being used.
patients in large numbers. Poor pricing
Hospitals were overburdened as there was
and additional incentives to all healthcare
a sudden surge of patients. All these led to
workers added to the financial crunch.
huge expectations. Need for an unlimited
Less income increased material cost and
supply of oxygen, informing the relatives
additional
of the deceased, disposing of bodies and an
private
hospitals.
manpower
amidst With
hardly
payments
meant
most of the hospitals' health was at peril.
History always repeats itself only because mankind hardly learns from his blunder.!!!
26
December 2020
Uncertainty regarding the spread of corona
unrelenting media pressure made the task difficult.
virus is a new challenge and learning for
Even as the government fixed uneconomical
all. The SOP needs to be changed every
prices for COVID treatment, there are
other day depending upon the evidence.
opportunities
Healthcare workers dealing with COVID
post-covid. The other positive area was
patients are highly stressed and need
virtual consultation where the hospital
for
treating
patients
expenses were reduced substantially.
strategy implementation to reduce cost
Healthcare leaders assured productivity
and improve output. Survival of the
and cooperation from the hospital staff
fittest will ensure many of the hospitals
via constant motivation, counselling,
closing down because of the unhealthy
ensuring extra payment for COVID
financial conditions.
duties, quarantine quarters after COVID duties etc. However, the overall scenario led to no increments and no new job opportunities.
We hope that there is no repeat of 2020 as it was a year of bad dreams. Looking at the surge in COVID positive cases all around, we still have a long battle
Everyone needs to look beyond paying
to fight. Only the vaccine and the SMS
capacity. On many occasions, there
(sanitise, masks, safe distance) can save
were more confidence among the health
us from this pandemic.
workers managing the COVID patients as the work was conducted in a dedicated
History
always
repeats
itself
only
manner. Above all this is not a time to
because mankind hardly learns from his
look for profits but this is a time to take
blunder.!!!
care of the nation's needs.
The government should come up with
Hospitals need to be very stingy in
measures like rebates in essential areas
their approach and have to tighten
like electricity tariff and other taxes,
the belts further. Hospitals may not
reducing GST for all essential items,
invest in newer gadgets for the time
reducing import duties on life-saving
being and have to make the workforce
items and ensuring income tax reduction
lean and mean. The productive group
to healthcare workers. This is a better
needs to be incentivised and the non-
way to motivate the healthcare industry
productive might have to be gradually
and workers. The best time to start the
phased out. As healthcare sees itself
healing process from the government is
on a ventilator, it will mean some key
now than at any other time.!
www.indiamedtoday.com
27
COVERSTORY
VP Rajan Director, Veda Corporate Advisors
With the onset of COVID-19 pandemic,
KKR’s acquisition of JB Chemicals, Carlyle’s
investors took a wait and watch approach
investment in Piramal Pharma and Sequent,
through the second quarter (April-June) of
CVC investment in HCG, PAG led PE funds
the current year. While few transactions
consortium investment in Anjan Drugs were
moved ahead slowly given the macro
some of the big deals that happened since
situation, the change in business dynamics
April 2020. As you might have noticed, the
due to a series of lockdowns also led
list is dominated by pharma deals led by
to deferment of few other transactions. However, the overall pharmaceutical sector
There is an indication of green shoots in select pockets, especially medical devices and diagnostic services, which have been the beneficiary of a large number of COVID testing
28
December 2020
marquee funds.
remained resilient through this phase,
We believe that the situation continues to
thanks to the discomfort across the globe
improve each month with phased unlocking
arising from significant dependence on
of the economy and many healthcare
China for the pharma requirement.
businesses reverting to pre-COVID levels.
While the pharma sector continues to out beat other sub-segments of healthcare in terms of investor interest, there is an indication of green shoots in select pockets, especially medical devices and diagnostic
While
pharma
deals
will
continue
to
dominate through the first half of next year, we see deals in diagnostic services, medical devices and healthcare delivery likely to revive strongly from the second
services, which have been the beneficiary
quarter of the next year. With medium-term
of a large number of COVID testing,
to long-term outlook, healthcare companies
increased health and immunity awareness
are likely to work towards beefing up the
coupled with the need for a drastic increase
infrastructure, thereby kick-starting the
in healthcare infrastructure.
new cycle of investment for growth.
Sriram Natarajan Director, Molbio Diagnostics
Once the vaccination process starts and completes, we will know in time, what the future is likely to be
The pandemic - realistically speaking,
As cases picked up - adding to the number
threw all other facets of life out of gear.
of existing COVID beds (read ICU) in
It was chaos, to say the least. Even the
both public and private hospitals were
otherwise busy IVD industry - dominated
a challenge. The temporary set up was
by laboratory testing and other procedures
created within stadiums with full medical
took a hit. As indicated by a drop in
facilities to accommodate more cases, as
revenues - most facets of laboratory testing
numbers increased.
either diminish substantially or stopped as
Truenat COVID-19 test is surely one of
resources were mobilised for COVID-19
the innovations during this pandemic.
testing. Even emergency testing such as
It has enabled molecular testing using
screening of blood in blood banks etc. was
innovative RT-PCR tests be made available
hit and patients from non-covid sector took
from Arunachal in the East to Leh Ladakh
a back seat.
in the North. Every state was able to
Challenges
faced
ranged
appropriate
diagnostic
scale
up
them
to
from
tests
meet
getting
and
then
demands
to
providing more ventilators and critical care
deploy this state-of-the-art innovation in a district-wise
fashion
to
ensure
that
everyone who needed to be tested with RT-PCR - got tested. This not only saved on logistics on sample transport but also
equipment to COVID wards to save lives.
to an extent reduced the burden on Central
Making provision for medical grade oxygen
Laboratories from being inundated with
was also a challenge.
test requests.
www.indiamedtoday.com
29
COVERSTORY
Over five million Truenat COVID tests have already been utilised.
the future is likely to be. As the effects of vaccinations start
Other innovations like FELUDA also
showing up- we hope more lives will
needs a mention - however, their
be saved - the severe disease will be
utility will only be gauged once they
lesser. But the pandemic can be beaten
commercially hit the market.
only with a combination of vaccines,
Similarly, ventilators,
innovations
in
cost-effective
low-cost but
good
drugs and most importantly, responsible human behavioural changes of abiding
quality PPE kits — the repurposing of
by the rules.
certain medicines are all innovations
COVID-19 is not going to be the last
that the medical fraternity successfully
pandemic afflicting the human race - yet
tried in combating this pathogen - about
the world as a whole would have learnt
which still, we know so little about.
that ultimately it would be prudent six
to augment healthcare facilities for
to seven years, are being innovated
the human race - as no money, power
in ways to come out in a year. So
and military is good enough when the
innovations all around, I guess.
enemy is invisible - and the enemy is
Vaccines,
requiring
more
than
The pandemic is far from being over.
everywhere.
Yet as time passes and we begin to
Hopefully -priorities of humans will
understand lesser lives may be lost if
change - where one would be more
the human race behaves responsibly.
inclined to live life with nature as a
Once the vaccination process starts and
partner - and benefit from such an
completes, we will know in time, what
association.
30
December 2020
Ayanabh Debgupta Co-founder & Group President, Medica Hospitals
The impact
of the COVID-19 pandemic
personal protective gears for staff and
followed by nationwide lockdown is huge
testing of potential carriers among patients
which is visible across various sectors. The
and staff increased the overall operational
healthcare sector is at the epicentre of this
expenditure. Further quarantine measures
unprecedented crisis and has been gravely
for COVID positive staff affected the overall
impacted
in
workforce. Under certain circumstances,
demand
and
meeting
the
unparalleled
subsequent
financial
reached
out
to
their
staff
consequences. The pandemic is adversely
monetarily to support and encourage them
impacting the private healthcare services
during the pandemic. Adaptation of various
making a deep dent in the revenues of the
operational consolidation and cost-cutting
private hospitals.
measures were undertaken by private
Due to the fear of getting infected and
Making the right decisions and taking effective action will be possible only if new approaches to care delivery and financing are incorporated
hospitals
overall lack of liquidity in terms of regular cash flows, people with reasonable healthseeking behaviour avoided opting for treatment at private hospitals unless it became an absolute emergency. At Medica Superspeciality
Hospital,
the
service
hospitals across departments to ensure that business remains viable. Amidst low patient
footfalls
revenue
and
generation,
significantly the
low
government’s
decision to curb testing and treatment charges dealt a major blow to the hospitals. The healthcare industry should focus on
utilisation numbers fell below average.
sustainability,
Outpatient footfalls dropped below 50 per
comprehensive infection control measures.
cent, bed occupancy rate across all major
Building a digital health infrastructure,
private hospitals plummeted to 20-25 per
improving procurement and supply chain
cent with only deliveries and emergency
systems
procedures/surgeries
critical equipment will help in the long run
being
performed
and Average Revenue Per Occupied Bed (ARPOB) dropped by 30-40 per cent.
with
convertible
increased
designs
and
stockpiles
of
in case an emergency arises. Making the right decisions and taking
Patients postponed their elective surgeries,
effective action will be possible only if new
leaving aside the otherwise steady flow
approaches to care delivery and financing
of treatments related to chronic illness
are incorporated. Healthcare leaders must
such as dialysis, chemotherapy, blood
look into revamping some of the key areas
transfusion etc. Other services suffered a
of healthcare service delivery to bridge the
downfall with reduced patient footfall. Ban
gaps and meet the needs of the population
on international flights impacted medical
in case of an emergency of similar nature
tourism in the country.
in the future.
Patients visiting hospitals on emergency
Future
were considered as covid carriers. The
well prepared to battle pandemics and
need to sanitise premises and ensure
other
healthcare medical
systems
emergencies
should
be
whenever
www.indiamedtoday.com
31
COVERSTORY they arise in the future. There is a
to transport commodities will guarantee
need to critically evaluate our existing
timely delivery of items.
healthcare ecosystem, especially the critical care segment to determine our shortfalls in terms of the availability of
that are more resilient, patient-centred
an emergency plan and backup teams
and sustainable.
and resources. Whenever a similar pandemic strikes, an action plan needs to be in place that can be implemented in the shortest time frame – one that can
be
applicable
across
various
settings of our healthcare system by
and
motivated
resources
(HR)
are
adequate
health
human
essential
service
for
provision.
Healthcare leaders should not only focus on treating patients but also devote similar attention to the hospital staff’s
sufficient treatment centres, quarantine
physical and emotional health. Physical
and isolation centres without affecting
fitness and psychological counselling
the
sessions should be provided for the
bottlenecks
non-pandemic
population.
This
and
affected
staff. Hospitals should be by the side of
–
the family members of caregivers who
both in the healthcare segment and
succumbed to the deadly virus. This will
the
can
private
be
general by
involving
done
healthcare
hospitality sector which can become isolation units. Supply chain systems were the major enablers during the pandemic even during the restricted movement and operating environment. Supply chains
December 2020
Qualified
creating
removing
32
Thus, we need to build health systems
turn out a good example of compassion and care amongst the other hospital staff and enable an assurance. Appreciation
posts
through
emails
and display on staff notice board will
are under enormous pressure from end to
ensure a sense of recognition amongst
end during such emergencies, to ensure
the staff. Further timely remuneration,
delivery of lifesaving drugs, equipment
performance bonuses and appreciation
and medical supplies. Alternative means
gifts can boost the morale of the staff.
Ramesh Kannan Partner, Somerset Indus Capital Partners LLC
Investments
in
the
healthcare
sector
by Opex and cost linked to end-use. This
were hit hard during the lockdown due to
gave the sector a boost as more and more
COVID-19 pandemic.
The initial days of
technology companies swung into action
lockdown led to zero investments. Hospitals
to capitalise on digital health and SaaS
bore the brunt as deal flow completely
platforms. Also, consumables digitally were
evaporated. The providers were very much
the favourite as providers wanted savings
focussed on optimising operations, cutting
in purchases and dealing with a few instead
costs and preserving cash because the
of many. This enabled a lot of companies
future was uncertain.
to focus on creating models which helped
Few months down the line, pharma, API,
The healthcare sector is going to see an upside and digital health across sectors is going to play a very important role
providers to save and share.
health tech, digital health, SaaS, insurance
Digital health encompassing telemedicine,
tech, injectables, health consumer tech/
telecardiology, teleradiology, telepathology
diagnostics showed some signs of revival.
and teleICU found a lot of attraction and
While SaaS health consumer tech, digital
favour as it became the new norm of
health and health tech were the domain
consulting. Investments started blossoming
of VC’s and saw a substantial hike in deal-
in the second quarter and both VC’s and
making in the second quarter of this year,
PE’s were active with deal flows looking
other components were the domain of
positive.
PEs.
Some large deals happened which
led to positive sentiment. Hospitals were impacted while diagnostics (thanks to Covid testing) saw a spurt in revenues and profits on one side and national players were looking at regional presence (in an organised fashion) on the other.
Currently, things are far better in the third quarter as the pace of investments has gone up both with VC’s and PEs. Deal flow is looking good and many deals are likely to be closed in the fourth quarter of this financial year. The healthcare sector has bounced back and hopefully will be in the
Pharma was the biggest gainer as the entire
pre-COVID phase by the end of this calendar
sector did very well and deal flow was robust.
year or maximum first quarter of next year.
There was an opportunity both within and
The digital health sector is going to be big
outside the country and this catapulted the
and operational finance compared to capital
sector to newer opportunities. Added to the
finance is going to play the roost. A lot of
fact was significant interest in API’s thanks
companies are bundling their products and
to the China problem and there was a lot
services and customers are being offered
of interest in deal-making. SaaS models
payments with upfront concessions linked
saw an increase as capex was replaced
to
earnings.The
consumer
health
and
www.indiamedtoday.com
33
COVERSTORY consumer tech sector particularly in
favoured backed by the need from the
areas where services are being moved
elderly, expected mothers and newborn
from showrooms to homes are doing
/children which will eventually lead to
very well. Particularly in the retail
consolidation and growth.
space, a lot of interest in companies which can meet the requirements of both products and services at home are facing an upside.
The healthcare sector is going to see an upside and digital health across sectors is going to play a very important role. The health insurance sector is going to
Very clearly, in the new year, while
get a very big boost and grow very fast.
hospitals on a larger scale (network
Digitisation is going to enhance value.
hospitals) could see some action, the focus is going to be on the PE side for the pharma sector and health tech on the VC side. There is bound to be M&As flowing in the larger deal pipe. While the bigger players would like to consolidate, medium players would like to increase the size and scale so that they are found to be attractive by the larger players.
Patient’s
safety
importance. institutions,
is
of
paramount
Development impact
funds,
finance NBFC’s,
venture debt and structure debt etc. focussed on healthcare and its revival. Technology will play a very important role going forward as companies will leverage technologies to offer more. Manufacturing in India got a thumbs
There could be some deals on the health
up which is a positive sign considering
tech side which can result in some
more
consolidation and increase in size and
requirements are imported. Screening,
scale. SaaS is bound to see an increase
prevention, remote care of infectious
in activity and spreading in different
disease etc. will see a big boost. We
subsectors. The home care sector which
shall all remember that quality is the
was much neglected initially is being
focus and the key to success.
34
December 2020
than
80
per
cent
of
our
Meena Ganesh MD and CEO, Portea Medical
The pandemic has shown that there is a need to reimagine public health systems and create a new healthcare model that is affordable, accessible and effective
COVID-19 hit the world suddenly, at a
need to reimagine public health systems
time when no one predicted it. The scale
and create a new healthcare model that
of the pandemic and the subsequent
is affordable, accessible and effective.
nationwide lockdown was unprecedented.
While all of the healthcare cannot be done
Healthcare was the most directly impacted
remotely on digital platforms, we can
as old operating models went out of the
still ensure primary healthcare delivery
door. Overnight, there was a need to learn
through
to diagnose, assist and treat remotely
facilities. Coupled with Ayushman Bharat,
whenever possible. There was an increase
it is possible to bring high-quality primary
in the demand for home healthcare services
healthcare to every India. However, all this
given the rising burden on hospitals and
needs to be done on a war footing and
the fear of contracting the infection. At
through a joint effort between the public
Portea Medical, we mobilised our troops,
and private sectors.
partnered with governments and provided home isolation services to hundreds of thousands of afflicted patients. With the prolonged impact of the pandemic, the home healthcare sector will continue to see massive growth going forward as well.
diagnostics
and
treatment
My leadership team and I travelled all the time to the 22 cities we operate in to understand and manage operations. It was important to motivate our teams in each city by spending time with them and observing operations first hand. The
The last few months have been a big learning experience in terms of dealing with a crisis while working remotely all the while. It is important to reimagine the company direction, products and services, and go-to-market strategies. The most important role of the leader is going to be constantly scanning and modifying the direction as things get clearer. The pandemic has shown that there is a
pandemic also provided a great opportunity to meet patients and their families to understand their problems and help solve them. During this time, we repurposed our technology and medical capability to help governments remotely monitor COVID positive home isolated patients. We are associated with six different state governments to provide these services in their respective jurisdictions. So far, we
www.indiamedtoday.com
35
COVERSTORY have delivered services to treat more
have ushered in the era of out-of-
than 100,000 COVID positive patients,
hospital healthcare in India. During
of which less than 3 per cent needed
this period, people have experienced
hospitalisation. This solution is now
the benefits and efficiency of home-
being offered by us to corporates and individuals too. We also used our existing digital capabilities to support this change in patient mindset by supporting them. Going forward, we are focusing a lot more on digital solutions,
based like
healthcare telemedicine
services.
Options
consultations
are
digital processes that can function effectively even when normal social life is disrupted and patients are not able to travel to a conventional healthcare facility or clinic. This will bolster the
and integrating them better with our
overall healthcare quality in India and
existing on-ground services.
will enable quality healthcare services
The innovative services offered in the healthcare sector during the pandemic
36
December 2020
to cover all parts of the country including the remote or rural areas.
Rajiv Nath Forum Co-Ordinator, AiMED
As India geared up to fight the COVID-19
The
crisis, the Association of Indian Medical
Incentive)
Device Industry relentlessly worked at the
investments and Make in India for high-
forefront to combat the crisis. Huge efforts
technology product segment of medical
were put into increasing medical device
devices and the medical devices park
manufacturing capacity by AiMeD through
promotion scheme by DoP are further
its members and beyond.
encouraging growth in this sector which
AiMeD worked closely with the Government
COVID-19 crisis has shown that the Indian medical devices sector can rise to the challenge
recent
PLI Scheme
(Production to
Linked
encourage
has been challenged by cash flow upsets by delayed payments from government
of India i.e. Dept. of Pharmaceuticals,
buyers. We are seeking supportive policies
Ministry of Commerce, NPPA and CDSCO
of nominal tax protection, separate medical
for ramping up capacity and addressing
device law that does not criminalise minor
production bottlenecks during the pandemic
offences, preferential pricing for domestic
to fight against COVID-19 pandemic during
manufacturers in government procurement,
the complete lockdown period.
restriction in the import of pre-owned
AiMeD
worked
with
QCI
to
expedite
finalisation of ICMED Plus Certification as well as with consultants consortium to provide online training on quality management new
system
entrepreneurs
garments,
textile,
certification from
auto
to
automakers,
parts
Industry
who had ventured into medical devices
medical equipment and price cap of import landed / ex-factory prices at rational levels as strategic support policies. These will encourage
manufacturer-turned
traders
to go back to manufacturing and seek collaboration and joint ventures globally and use the infrastructure being provided in these upcoming medtech parks.
manufacturing. COVID-19 crisis has shown that the Indian medical devices sector can rise to the challenge. When imports got disrupted, specific devices detailed with quantified production shortages and a focussed InterMinistry Group coordinating with domestic manufacturers via AiMeD had addressed production bottlenecks and challenges so that not only capacity got utilised but also ramped up rapidly.
www.indiamedtoday.com
37
COVERSTORY
Sudhaker Jadhav Chief Operating Officer, Oasis Fertility
When the nation called for a complete
considering a second wave of the pandemic.
lockdown on March 24, it was a chaotic
Our priority was to give a very high degree
situation and many IVF centres in the
of safety assurance to our patients and all
country were forced to pause putting a lot
our staff and stringent safety protocols
of pressure on the system with no revenues.
right from the patient’s phone call to the
There was no visibility and certainty as to
centre till she gets her embryo transferred.
when the pandemic would end. There were almost two months of zero revenues in the industry and only in late May and in early June, the IVF centres started to resume
I feel that next year could get better as there will be a spike in footfall at IVF centres and also people per se will feel safe going to a stand-alone clinic vis-a-vis a fertility centre being operated within a multispeciality hospital or a mother and child hospital
their operations. Liquidity was a major issue and of course paying salaries to our staff and medical teams were the biggest
According to a Grandview research report, Asia Pacific accounted for the largest share in terms of the number of IVF cycles
to 60 days which taught us how to fight this pandemic. Looking back, we at Oasis Fertility feel that we have come a long way in setting up some decent safety protocols.
taught us to be considerate and empathetic towards people and restricted us from spending money on a luxury.
performed in 2019, with Japan, China, and
I feel that as healthcare leaders, we need to
India being the major contributors to the
reassure our employees and their jobs. We
region.
always believed that patients come second.
The India IVF Services Market garnered
We have a clear understanding that a
$478.2 million in 2018 and was expected
happy employee makes a customer happy.
to reach $1.45 billion by 2026, at a CAGR
We take a lot of pride that at Oasis Fertility
of 14.7 per cent from 2019 to 2026.
we never displaced or laid off any of our
potential
of
COVID-19
severe
pandemic necessitated the development of an organised and well-reasoned plan
employees and during the tough time, we showed them the solidarity by paying the salaries.
embryology/
Second, I think we should be more proactive
andrology laboratories while safeguarding
and anticipate the situation to continue
the wellbeing of patients and IVF staff. We
for another year or so and start planning
at Oasis Fertility created an indigenous
resources for our goals. We all know that
and exhaustive SOP and road map even
online consultations have grown a 1000
for
December 2020
learn from the past, it was those crucial 45
On a different tangent, I think COVID-19 has
priority for us at Oasis Fertility.
The
38
There was no reference point for us to
the
management
of
fold but unfortunately in IVF treatments
On the patient front, we had launched
like IVF consumables and pharmacy.
it doesn’t work that way as the patients
a
engagement
We have been talking to the leaders
have to come to the centre, But,
platform which makes the IVF journey
from the supply side to look at a price
however, we have tried and reduced the
for a patient very smooth, right from
revision. Some aggregators are playing
no of visits by launching IVF at home
the booking of the appointment to the
a decent role a decent role who can
and also doing a lot of things remotely
day of the embryo transfer.
such
as,
registrations,
appointment
contactless
patient
bring down the cost per cycle. We feel
We at Oasis Fertility are sensitive about
that these kinds of aggregators should
booking, history taking, counselling and
the needs of the patients. We have a
be encouraged who can bring in a lot of
patient education which is now done
deep understanding of the customer
totally contactless.
value on board for both the IVF space
demographics and have also understood
and the patients.
We anticipate that the next financial
that money has become dearer. We
year would be better.
came up with some very aggressive
As
mentioned
earlier,
engagement
was
our
during
lockdown
top
employee priority
economical packages to cater to the patients thereby continuing
of
the great level of patient satisfaction
just not supporting them financially
and also offered them zero per cent
the
in
terms
by assuring their salaries but also frequently checking on the well being of
EMI options through different fintech companies.
I feel that next year could get better as there will be a spike in footfall at IVF centres and also people per se will feel safe going to a stand-alone clinic visa-vis a fertility centre being operated within a multi-speciality hospital or a mother and child hospital. The numbers would be very positive as
them and their family members. There
I think the industry leaders should
were instances where our admin team
look at curtailing the spiralling cost
ensured a seamless supply of groceries
of IVF and pass on the benefits to the
to corona will ease out and also hoping
and other essentials to our employees
patients. This is possible if the revisions
that by the starting of the coming year
who were COVID positive.
happen right from the supply side
we might get a vaccine.
the demand which was restricted due
www.indiamedtoday.com
39
COVERSTORY
Dr Biren Chauhan
Group COO, Sunshine Global Hospitals
We all can debate and discuss at length
hospitals and they consolidated and refined
if we start evaluating the pros and cons
their covid care delivery model in no time
which the lockdown won across sectors
and went back to routine work in less than
in the country. But we all agree to the
three to four months.
fact that hospitals operate and reflect the healthcare needs of the community/ city/ state that they operate from and hence
Overall, healthcare in India will be a lot different in terms of patients, providers and payers in the coming years and uptake of services will be more than ever
cannot escape the impact of micro or macro-level policy decisions in response to COVID-19 Pandemic. The lockdown had a varied impact from mid-March till date and will have for the near term future too.
providers
and
payers
were
working
very closely to fight the pandemic in the latter and end phase of the lockdown. It is reasonable to say that the principle of 'survival of the fittest' was tried, tested and proven true once again amidst the pandemic. Foundations of humanity and its
private hospitals had the only emergency
value system was yet again at its best peak
and critical care patients flow as the fear
and the fighting spirit of the human race
of COVID-19 and complexity of COVID care
was once again at its full display.
restricted both patients and the providers to get themselves ready for the new normal. As cases kept on rising amidst the
The learnings from pandemic will have long-lasting ramifications and we will see a
lockdown, the mid-phase of the lockdown
set of new rules emerging to better manage
saw hospitals offering COVID-19 care to
Hospitals. Futuristic planning will have
the patients by the caseload in and around
the inherent component of being flexible
the hospitals. Many hospitals converted
to
themselves into designated covid care
unfolding outside the healthcare domain.
hospitals and others into non-covid or
Hospitals
between covid and non-covid patients.
December 2020
need was done at all levels where patients,
During the initial phase of the lockdown, all
mix care models with physical segregation
40
Capacity enhancement as per the local
accommodate
that
got
unforeseen
away
changes
early
from
financial and non-financial stress on their functioning were also the ones that were
The mid-phase threw a range of challenges
first to mould themselves as per the need
from manpower to resource management
of the new normal. Being cost-effective
to care protocol and limited treatment
is the most important catalyst for turning
protocols, etc. All stakeholders like the
around any situation to an advantage.
federal government, state and district
Developing and nurturing spectrum of
administration,
private
the multi-faceted and diverse manpower
partnerships flourished in this challenging
resource pool, enabling outlook-oriented
time of COVID-19 Pandemic. Gradually the
systems capable enough to adapt to new
new normal was achieved by the private
challenges and value and ethos driven
public
and
organisations are more immune to the
can be done without any friction only
sharing between hospitals in the same
threat of COVID-19 on its functioning.
when a participative culture exists in
region is also a good sign and will help
hospitals. Rather than having quick
everyone to improve their performance.
hire and fire, hospitals must protect
Trust and respect of the community
and support its workforce during the
towards
pandemic and beyond. It will surely
have increased tremendously because
shape up the hospital's workforce as its
of COVID-19.
COVID-19 care offering at an affordable cost has been possible only for those hospitals who are good enough to keep
themselves
cost-effective
by
adopting innovative cost optimisation models.
Cost-effective
solutions
strength.
their
healthcare
providers
Deploying technological solutions and
without compromising on quality have
Similarly removing avoidable wastages
reaching to patients by innovative
been the trademark of sustainable
and
solutions will unlock the future potential
hospitals amidst the pandemic. Also,
competitive edge to hospitals. Working
of
successful
with vendors, partners and associates
around have become vigilant towards its
in
hospitals
in
COVID-19
optimising
will
a
healthcare
success.
Communities
purchase,
health and well being and will improve
BME, engineering and maintenance,
population health on a longer run.
hospitals stand out as a differentiator
outsourced services, etc will give needed
Overall, healthcare in India will be a lot
and determinant of the success of the
leverage by having cost optimisation
different in terms of patients, providers
hospitals in these challenging times of
of around 7-10 per cent over the next
and payers in the coming years and
the pandemic.
year or two in this segment. All these
uptake of services will be more than
would be possible when hospitals have
ever. Hopefully, disease patterns will
an inherent culture of sharing and
also change from communicable to
caring and positive attitude towards its
non-communicable
doctors, human resource, vendors and
diseases
associates. It can not happen overnight
behaviour will change for the larger
and
empathetic,
good. Governments will no longer be
participative and supportive leadership
able to ignore the basics of healthcare
will be critical to the success of cost
and they will have to deliver to ensure
optimisation efforts during COVID-19
that social determinants of healthcare
that
leadership
capabilities
The pandemic has changed monthly, quarterly and annual projections for hospital leaders. First and foremost, leaders
must
rework
and
redraw
projections and bring them closure to reality after considering the pandemic. Strong understanding of the virus, its multi-pronged interaction with micro and macro environments at global, national, state and community level will
I
firmly
general
give
and performance-oriented culture of
showed
pharmacy,
cost
believe
and post-COVID scenario.
and
and
infectious
healthcare-seeking
and gaps are addressed in a time-bound
surely be an added advantage. Once
FY 2020-21 will be marked as an outlier
manner. The local administration has
it is done, the next logical step would
financial year for almost all hospitals
seen a devastating impact of COVID-19
be to assess the bottom-line expenses
irrespective of whom they cater to
in the lives and livelihood of one and
of all types (direct and indirect, fixed,
(COVID or non COVID or both). On a
all. They will also give healthcare
variable and semi-variable, etc).
brighter side, hospitals will be more
much-needed attention and priority by
flexible and will not shy away from
strengthening primary and secondary
quickly changing their service offering
care delivery systems at grassroots
as per the needs of the community
levels.
Leaders must prioritise the areas where they can optimise as per the need of the
hour,
for
example,
considering
innovative ways to address fix cost/ minimum
guarantee
specialist
doctors
committed and
to
engaging
around. Also, hospitals will be quick to take radical decisions to ensure their viability.
Overall, the outlook for FY 21-22 is very promising and we’ll witness a more transparent, more coordinated
them in an empathetic way. Once
Hospitals will be likely to keep their
healthcare delivery system with the
they understand the real picture of
legal
in
government’s role that will take a
the pandemic and its impact on the
check. Communication with different
paradigm shift from being a regulator
financial health of the institute, to help
stakeholders within and outside the
to the facilitator. The public health
organisations become viable in coming
hospitals
cornerstone.
and healthcare delivery system will
months, doctors will stand together
A lot of hospital leaders are now
be closer to each other than ever and
with the institute and willingly take
closely working with local government
we hopefully will see a holistic care
proportional hits in their payouts and
administrations and this will be good for
delivery model across the country in
help the institute in difficult times. This
the communities around. Information
coming years.
and
statutory
will
be
compliance
the
www.indiamedtoday.com
41
COVERSTORY Dr Subhrojyoti Bhowmick Clinical Director, Academics and Research, Peerless Hospital
The year saw telemedicine practice guidelines come into existence in India and teleconsultation for patients is here to stay even in absence of the pandemic
42
December 2020
Looking back on the eve of December 31, 2019, I remember how excited we were to welcome a new decade of hope and prosperity, where we had no clue of the unprecedented crisis we have to face in 2020 - how it holds the capability to have changed all of our lives forever. 2020 has taught us many lessons and given us many wake up calls. Millions of people around the world have died during the pandemic. Millions in India alone have lost their jobs. Though China was struggling with this deadly virus since the end of 2019 not all of their struggling moments were clear to us at the time. China’s decision to shut down cities of millions of people in early January was staggering, however to most Indians; this new coronavirus 2019 (COVID19) remained a distant nightmare, not something that would demand our version of a lockdown. However, amid the virus spreading news from China, France and Italy, the coronavirus outbreak was declared a pandemic on March 11, 2019, by the World Health Organization (WHO) and many of us are already feeling nostalgic for our lives by the time it went global. Slowly yet steadily we were into this biggest crisis of humankind ever thought of.
warriors. Praying day and night to receive the
Every person around the globe has had their taste of fear, anxiety, and uncertainty to face from March 2020. All the blessings we enjoyed and have taken for granted since our childhood have suddenly started taking a toll. Many families are infected in front of our eyes. Some are moving on with caution and care, however, those who are reckless are endangering their lives as well as others. In the middle of all this uncertainty and losing lives, all we are left with is hope. People were looking with all their hopes for frontline
COVID19 outcomes. AI utilises deep learning
“magic vaccine” from the healthcare industry. 2020 made us focus on infection control practices like hand washing and wearing masks as the way of life to beat the virus. Never have neither the healthcare professionals nor the common people have fully complied with these infection control practices. This year the major emphasis was on vaccine clinical trials and media coverage of phases of clinical trials made these topics a household story. The year saw telemedicine practice guidelines come into existence in India and teleconsultation for patients is here to stay even in absence of the pandemic. On the same line, Artificial Intelligence (AI)driven technology enhancement is happening in the field of radio-diagnosis and laboratory medicine in much higher healthcare centres of the country. AI is not only assisting children to learn better by enlisting tailored teaching assistants but also by helping with smarter energy consuming like the US and the UK AI is analysing and uncovering patterns in huge swathes of medical data and this makes it the perfect tool for modelling and tracking models, which has also been deployed to support drug discovery that can combat the virus. Over this year, AI has been continuously used to solve some of healthcare’s most pressing issues – from reporting the power of medical records, to relieving doctors and nurses from contact-tasks, to enhancing surgical precision to a great extent, yet much more is yet to come in the next few years.
www.indiamedtoday.com
43
PULSE
Oxford-AstraZeneca Vaccine is Cheaper than Pfizer’s and
Moderna’s and Doesn’t Require Supercold Temperature The biopharmaceutical company AstraZeneca has released data on what is now the third promising vaccine candidate against COVID-19 – and it has several advantages over those of its competitors, Pfizer and Moderna.
Sanjay Mishra Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
On Monday, AstraZeneca released interim analysis of its phase 3 trial data of 23,000 volunteers from the U.K. and Brazil. These results show that the test vaccine is between 70% and 90% effective in stopping COVID-19, depending on the vaccine doses administered. Although less effective than the reported results from the Pfizer or Moderna COVID-19 vaccine candidates, this vaccine is still more effective than annual influenza vaccines that reduce the risk of flu by between 40% and 60%. Notably none of the vaccinated participants needed hospitalizations or reported severe disease. Like most vaccine experts, I am intrigued by large differences in effectiveness between two tested dosages of AstraZeneca’s vaccine. Until March, I was developing vaccine candidates against Zika and dengue. Now I am coordinating a large crowd-sourced international effort to better understand the scope and severity of COVID-19 in cancer patients. The COVID-19 vaccine trials generally exclude most people with a history of cancer, so I am eagerly awaiting vaccine efficacy data for this risk group when these vaccines become widely available.
Intriguing dose response AstraZeneca’s vaccine was originally planned to be given in two full doses, four weeks apart, as injections in the upper arm. A third of the volunteers were injected with a dummy saline placebo. One of the few details that AstraZeneca released is that of 131 cases of COVID-19, only 30 cases were detected among 11,636 who were given the vaccine; 101
44
December 2020
cases occurred among the volunteers who got the placebo. That suggests that the vaccine is 70% effective overall. However, an error in the early stages of the trial meant that some participants received only a half-dose in the first round. In the group of 2,741 volunteers who received a lower dose of the vaccine candidate followed a month later by a full booster dose, the efficacy was 90%, according to AstraZeneca. The efficacy was only 62% among the 8,895 volunteers who received both full doses. It is not clear why the half-dose plus the full dose sequence of the vaccine performs better than two full doses. One explanation could be that since the vaccine is based on a common, although nonhuman, cold virus, the immune system probably attacks and destroys it when the first dose is too large. It is also possible that progressively increasing the dose more closely mimics a natural coronavirus infection. Beginning with a lower first dose might be a better way of kicking the immune system into action; then a stronger, more effective immune response occurs after the second full booster dose. Despite enormous progress in human immunology, scientists still don’t understand the best strategies for inducing protective immunity. These results are based on the evaluation of about one-third of volunteers who are expected to participate in this trial, which is ongoing in other parts of the world and will enroll up to 60,000 people. AstraZeneca will now seek approval from the FDA to also evaluate the half-dose protocol in the ongoing U.S. trial. The current trial involves 30,000 participants and is evaluating only the two fulldose regimen. AstraZeneca’s trials in the U.S. were halted temporarily in early September after a study participant in the
U.K. fell ill, but resumed in the U.K., Brazil, South Africa and Japan.
A modified chimpanzee cold virus The
Oxford-AstraZeneca
vaccine
is
another example of a new strategy being used to rapidly develop vaccines against the coronavirus that has already infected over 58 million people worldwide. A vaccine works as a primer to train the immune system against a pathogen. Conventional
vaccines
are
made
by
weakened viruses or by purifying their disease-causing protein, such as the spike protein, which decorates the surface of a coronavirus. But these methods can take decades to develop new vaccines. Coinvented by the University of Oxford and its spinout company, Vaccitech, this vaccine uses different molecular tools to provide a preview of the SARS-CoV-2 virus to the human body. Instead of making weaker viruses, or delivering mRNA that encodes the spike
Not-so-frigid storage requirement Despite a somewhat later arrival, with less than the effectiveness claimed by its competitors, AstraZeneca’s vaccine might be favored because it can be stored, transported and handled at standard refrigerated conditions of between 36 and 46 degrees Fahrenheit for at least six months. The competing mRNA vaccines by Moderna and Pfizer/BioNTech require ultracold temperatures for stability. So the AstraZeneca vaccine will be easier to use in normal clinics, especially in rural America and the developing world. Another important advantage of the AstraZeneca vaccine, which is being tested in collaboration with a larger number of global sites, is that it should cost less because of AstraZeneca’s commitment to COVAX, a global initiative that aims to distribute low-cost vaccines to lowand middle-income countries. Pfizer and Moderna have not joined the COVAX
initiative, but AstraZeneca has agreed to make the vaccine on a not-for-profit basis for the duration of the pandemic.
Wait and watch However, like all other candidate vaccines for COVID-19, AstraZeneca’s vaccine is also lacking in key details such as the breakdown in infections, the durability, or the efficacy in the different age groups of trial participants. For all the vaccine candidates, we have only preliminary data from a small number of infections, and none of the groups developing the COVID-19 vaccine candidates has so far published complete data. So it is difficult to fully assess the differences between them. We will have to wait for more followup and longer-term data to evaluate the effectiveness of all the COVID-19 vaccines in finally getting the COVID-19 pandemic under control. This article is republished from The Conversation under a Creative Commons license.
protein, as Moderna and Pfizer did, the Oxford vaccine packs the DNA that codes for the spike protein in the shell of a genetically altered chimpanzee virus. The original adenovirus causes common cold in chimpanzees and it rarely, if ever, infects humans. The virus is further modified to ensure that this chimp virus cannot grow in people. The AstraZeneca vaccine uses the modified virus as a vehicle to deliver the COVID-19-causing spike or S-protein of the SARS-CoV-2 virus. Under the agreement with the University of Oxford, AstraZeneca is responsible for development, worldwide manufacturing and distribution of the vaccine. This isn’t the first time that University of Oxford scientists have tried a vaccine using this harmless virus. Previously, it tested the concept against a closely related coronavirus that causes Middle East
respiratory
syndrome
(MERS)
in
animal studies. So this time, soon after the sequence of the novel SARS-CoV-2 became available, the Oxford scientists retooled the chimp virus for a vaccine that induced robust immune response against SARSCoV-2 in mice and rhesus macaques.
Genetic material encoding the spike protein, which enables to infect human cells, is inserted into a modified cold virus from chimps. This combination is the OxfordAstraZeneca vaccine that was then injected into volunteers. The vaccine allows the muscle cells in the arm to manufacture the spike protein, which gives the body a preview of the virus and allows it to develop an immune response should the real virus strike. University of Oxford, CC BY-SA
www.indiamedtoday.com
45
APPROACH
We need these two policies to drive our recovery from COVID-19 Mandeep Dhaliwal
With more than 54 million cases of
Director of HIV, Health and Development Group, United Nations Development Programme (UNDP)
COVID-19 reported globally at the time of writing, many countries are struggling with second waves of the virus. The prospect of reimposing lockdowns and other restrictions, while necessary to bring the pandemic under control, could have devastating economic and social consequences for millions of people. At the same time, many initial government
introduced the 'Solidarity Income' scheme to deliver resources to an additional 3 million vulnerable households. Meanwhile, the government of Togo gave over $19.5 million in monthly digital cash transfers to more than 12% of its population, mostly to women who work in the informal sector. But temporary financial assistance is not
cash assistance to the most vulnerable are
enough. Without affordable healthcare,
coming to an end.
these types of programmes will inevitably
millions of people who lost their jobs or are struggling to make ends meet amid the pandemic must make difficult choices about how to use their limited resources.
fail to stimulate the economy and prevent financial hardship for the poorest and most vulnerable communities. United Nations Secretary-General
AntĂłnio
Guterres
underscored this reality in his recent
For many, the choice between spending
call for countries to urgently scale up
money on medical expenses or necessities
investment in universal health coverage to
like food and shelter is, quite literally, life
help end the crisis and build back stronger.
or death. Even if such social and economic
As he put it: “A huge gap in health coverage
protections continue, the lack of widely
is one reason why COVID-19 has caused so
accessible and affordable health services
much pain and suffering.�
means one medical bill could still force a
Women, for example, comprise 89% of
family into extreme poverty.
the informal economy in Sub-Saharan
Policy-makers must use a combination of
Africa.
tools, including both immediate measures
as street vendors or domestic workers
like temporary basic income (TBI) and
with no social protections, could face
urgent changes like achieving universal
enormous financial burdens due to health
health coverage (UHC), in their response.
costs that would erase any economic
Only then can we recover from the
gains from TBI programmes. Even before
pandemic and build back more resilient
the pandemic, 100 million people were
and sustainable communities.
pushed into extreme poverty each year
Several countries across income levels have
already
implemented
successful
programmes to mitigate the financial impact of the COVID-19 pandemic. A recent
December 2020
The Colombian government, for example,
stimulus plans that provide emergency
Without these programmes, hundreds of
46
effects of the crisis.
These
informal
workers,
such
because of healthcare costs. COVID-19 has only exacerbated this crisis, with disproportionate impacts on women and other marginalized groups.
United Nations Development Programme
Despite
(UNDP) report affirms that temporary
workers might forgo COVID-19 testing and
income
assistance,
informal
basic income policies can help protect
unknowingly contribute to the spread of
poor families that lack social assistance
the pandemic due to the lack of affordable
or insurance protection from the worst
and accessible health services in many
communities.
of
more effectively address the virus itself
COVID-19 is disrupting other life-saving
Moreover,
the stress
and its disruption of essential health
health services in these communities,
services and its socio-economic impacts,
such as childhood immunization, HIV, TB,
malaria,
family
maternal
planning
and
health
care,
treatment
for
while contributing to long-term societal and economic resilience.
non-communicable diseases like diabetes
Studies show that achieving UHC is an
and high blood pressure. These ripple
ambitious but attainable goal, even for the
effects multiply and could have harmful
world’s poorest countries. Equitable access
long-term
to affordable, high-quality healthcare is
effects
for
individuals,
communities and national economies.
the foundation for resilient health systems
No one should be forced to choose
that can respond in future emergencies
between their health and their financial
and deliver essential services in times of
security. Investing in temporary basic
both crisis and calm.
income programmes and universal health coverage is the best strategy for long-
Temporary basic income can mitigate
term recovery by ensuring that people
some of the worst effects of COVID-19
can access the health services they need
on poor households, and universal health
without facing serious financial difficulties.
coverage is critical to ensuring strong
And it is possible to do both.
health systems that don’t drive people
UNDP found that the majority of TBI
into poverty – now or in the future. Both
schemes would cost most developing
will take political will and investment, but
countries far less than 1% of their GDP per
now is not the time to limit or pull back. To
month while providing substantial benefits
respond effectively to COVID-19, countries
to
need
should implement a smart combination of
assistance to buy immediate necessities
measures that will accelerate economic
vulnerable
populations
who
like food for their families.
recovery while providing the foundation
While countries have agreed to work
for more equitable, just and sustainable
toward
2030,
development. Only then can we protect
we must accelerate this process to beat
the most vulnerable during this pandemic
this
and prevent future health and economic
implementing
pandemic
and
UHC rebuild
by
stronger
than before. For these precise reasons, Secretary-General Guterres has outlined how investing in UHC will help countries
crises. First published on World Economic Forum under a Creative Commons license
www.indiamedtoday.com
47
HEALTH-IT
Lurking cybercrime in healthcare sector How financially motivated criminal groups continue to target the healthcare industry via ransomware attacks and the ways to prevent such attacks In 2019, the global healthcare industry
data
saw a substantial increase in the number
credentials. Criminals are after one piece
of breaches and incidents. Out of 3,950
of information – personally identifiable
confirmed breaches, the number of data
information (PII) and protected health
breaches in this sector came in at 521
information (PHI). Your PII or PHI may
versus 304, in 2018. Verizon’s Data
be collected or created by a healthcare
Breach
Prashant Gupta Head of solutions South East Asia & India, Verizon Business Group
data
and
provider, health insurer or employer. The
motivated
criminal
information can usually contain a person’s
groups continue to target the healthcare
name, address, phone number, medical
industry via ransomware attacks. Lost
insurance details, beneficiary information,
and stolen assets also remain a problem
financial account numbers, biometric data,
while basic human error is alive and well
facial images etc. There is a tremendous
financially
applications and phishing or business email compromises represented 72 per cent of breaches in the healthcare sector.
December 2020
medical
revealed
in this vertical. Miscellaneous errors, web
48
by
Report
that
Investigative
followed
amount of information flow in healthcare – prescription information sent from clinics to pharmacies, billing statements mailed, discharge papers physically handed to
The majority of the data under attack
patients, copies of identity and insurance
in
cards filed and so on.
the
healthcare
sector
is
personal
In my opinion, unless you really protect
actors fall to 48 per cent. However, this is
data at its core, no matter how many
a small percentage, and healthcare remains
network-level
the industry with the highest amount of
protection
or
endpoint
level protections you put in, it won’t really keep you secured for too long. Healthcare organisations need to conduct a proper risk assessment to prioritise investments and focus on the issues that matter the most and mitigate the risk or bring the risk to an acceptable level. These organisations need
to
approach
follow to
the
defence-in-depth
safeguard
their
critical
systems and data as our research tells us
internal bad actors. As with many things in life, as one attack grows more prevalent, others begin to decrease. So the story goes with the miscellaneous errors pattern. While it has frequently graced the top three patterns in this sector, it took the gold this year. In case you are curious, the top mistake within
healthcare
is
our
old
friend,
misdelivery.
that by increasing the number of layered controls (in essence the number of steps
This error tends to fall into two major
that an adversary has to clear) to protect
categories:
systems/data could be very effective in
• Someone is sending an email and
decreasing the probability of occurrence
addresses
of a data breach.
frequently wider) distribution—it’s a
In the 2019 report, we showed Privilege
bonus if a file containing sensitive
Misuse at 23 per cent of attacks, while in
data was attached with their patients,
2020, it has dropped to just 8.7 per cent.
they create additional lucrative attack
Does that indicate that insiders are no
surfaces.
it
to
the
wrong
(and
longer committing malicious actions with
• An organisation is sending out a mass
the access granted to them to accomplish
mailing (paper documents) and the
their jobs? Well, we wouldn’t go quite that
envelopes with the addresses become
far. However, it will be interesting to see if
out of sync with the contents of the
this continues as a trend when next year’s
envelope. If sampling is not done
data comes in.
periodically throughout the mailing
Another change that goes along with decreased insider misuse breaches is the corresponding drop in multiple actor breaches.
The
patients’ sensitive information. When thinking of the healthcare vertical,
typically been the leader in this type
one naturally thinks of medical data.
of breach—which usually occurs when
And, unsurprisingly, this is the industry
external
combine
in which that type of data is the most
forces to abscond with data that is then
commonly breached. However, we also see
used for financial fraud. The multiple actor
quite a lot of both personal data (which
breaches last year were at 4 per cent,
can be anything from basic demographic
and this year we see a drop to 1 per cent.
information
The 2019 DBIR reported a first in that
elements) and credentials stolen in these
the Healthcare vertical had Internal actor
attacks. The second most common pattern
breaches (59 per cent) exceeding those
for healthcare is the web applications
perpetrated by External actors (42 per
attack. As more and more organisations
cent). This year external actor breaches
open patient portals and create new and
are slightly more common at 51 per cent,
innovative ways of interacting with their
while breaches perpetrated by internal
patients, they create additional lucrative
internal
sector
NSYNC, then it’s bye, bye, bye to your
has
and
healthcare
process to ensure that they remain
actors
to
other
covered
data
www.indiamedtoday.com
49
HEALTH-IT
attack surfaces. Finally, we see a good deal of everything else pattern, which is not unlike a lost and found for attacks that do not fit the criteria of any other attack pattern. It is within this pattern that the business email compromise resides. If you’re not familiar with this attack, it is typically a phishing attack to leverage a pretext (an
Security Controls to provide you with
services and ports should be exposed to
a way to translate DBIR data into your
your systems, and limit access to those.
security efforts. Here are the top controls that our data suggest will be worthwhile for most organisations.
Boundary Defense: Go beyond firewalls to consider things like network monitoring, proxies and multifactor authentication.
Continuous
Vulnerability
Management:
Use this method to find and remediate
Data Protection: Control access to sensitive
things like code-based vulnerabilities; also
information by maintaining an inventory
great for finding misconfigurations.
of
sensitive
information,
encrypting
sensitive data and limiting access to
invented scenario to give a reason for
Secure Configuration: Ensure and verify
the victim to do what the attacker wants)
that systems are configured with only the
to successfully transfer money (by wire
services and access needed to achieve
Account
transfer, gift cards, or any other means).
their function.
accounts across the organization to keep
Although these are common attack types across the dataset, it is a good reminder to healthcare organisations that it isn’t only patient medical data that is being targeted.
and
Web
Browser
Protection:
authorised cloud and email providers. Monitoring:
Lockdown browsers and email clients to
Use of multifactor authentication also fits
give your users a fighting chance when
in this category.
facing the Wild West that we call the
Implement a security awareness and
Internet.
This year we’ve aligned our findings with
Limitation and Control of Network Ports,
both
the Center for Internet Security Critical
Protocols and Services): Understand what
accidental breaches.
December 2020
user
bad guys from using stolen credentials.
Recommended best practices
50
Lockdown
training programme: Educate your users, on
malicious
attackers
and
on
www.indiamedtoday.com
51
52
December 2020